<p>Cas9 Mediated Correction of β-<em>catenin</em> Mutation and Restoring the Expression of Protein Phosphorylation in Colon Cancer HCT-116 Cells Decrease Cell Proliferation in vitro and Hamper Tumor Growth in Mice in vivo</p>

Abstract

Colorectal cancer (CRC) is one of the major contributors to cancer mortality and morbidity. Finding strategies to fight against CRC is urgently required. Mutations in driver genes of APC or β-catenin play an important role in the occurrence and progression of CRC. In the present study, we jointly apply CRISPR/Cas9-sgRNA system and Single-stranded oligodeoxynucleotide (ssODN) as templates to correct a heterozygous ΔTCT deletion mutation of β-catenin present in a colon cancer cell line HCT-116. This method provides a potential strategy in gene therapy for cancer. Methods: A Cas9/β-catenin-sgRNA-eGFP co-expression vector was constructed and cotransfected with ssODN into HCT-116 cells. Mutation-corrected single-cell clones were sorted by FACS and judged by TA cloning and DNA sequencing. Effects of CRISPR/Cas9mediated correction were tested by real-time quantitative PCR, Western blotting, CCK8, EDU dyeing and cell-plated clones. Moreover, the growth of cell clones derived tumors was analyzed at nude mice xenografts. Results: CRISPR/Cas9-mediated β-catenin mutation correction resulted in the presence of TCT sequence and the re-expression of phosphorylation β-catenin at Ser45, which restored the normal function of phosphorylation β-catenin including reduction of the transportation of nuclear βcatenin and the expression of downstream c-myc, survivin. Significantly reduced cell growth was observed in β-catenin mutation-corrected cells. Mice xenografted with mutation-corrected HCT-116 cells showed significantly smaller tumor size than uncorrected xenografts. Conclusion: The data of this study documented that correction of the driven mutation by the combination of CRISPR/Cas9 and ssODN could greatly remedy the biological behavior of the cancer cell line, suggesting a potential application of this strategy in gene therapy of cancer.

EZH2 enhances proliferation and migration of trophoblast cell lines by blocking GADD45A-mediated p38/MAPK signaling pathway

“…Positively stained cells in five random fields of views were counted under the fluorescence microscope (FSX100, Olympus). The EdU-positive (proliferating) cells were stained in red and total cells were stained in blue [ 26 ].…”

AKR1B10 confers resistance to radiotherapy via FFA/TLR4/NF-κB axis in nasopharyngeal carcinoma

“…Quantitative real-time PCR (qRT-PCR) was performed as previous report 24 . Briefly, total RNA was isolated using Trizol® reagent (Molecular Research Center, USA) and 2 μg RNA was subjected to reverse transcription reaction to obtain cDNAs (Reverse Transcription System, promega, USA).…”

Application of CRISPR-Cas9 gene editing technology in basic research, diagnosis and treatment of colon cancer

“…Li et al used CRISPR/Cas9 and the single-guide RNA (sgRNA) system to construct gene editing tools to edit mutations in betacatenin driver genes and restore their normal biological functions. The b-catenin gene mutation has carcinogenic activity, and the growth of tumor cells is slowed down after mutation correction, which provides a new method for cancer gene therapy (87).…”